<p>One of the most vexing problems in cancer treatment is getting drugs where they need to go. Conventional chemotherapy floods the entire body with toxic agents, hitting healthy tissue alongside tumour cells. Even targeted therapies can struggle to penetrate the dense, oxygen-poor environments that solid tumours create.</p>
<p>A study published in March 2026 offers an elegant new approach: send bacteria in.</p>
<h2>The Tumour-Seeking Drug Factory</h2>
<p>Scientists have engineered <strong><em>Escherichia coli</em> Nissle 1917 (EcN)</strong> — a well-known probiotic bacterium that has been used safely in humans for decades — to function as a mobile drug factory inside solid tumours.</p>
<p>The key insight: solid tumours create low-oxygen microenvironments that are hostile to most cells, but that many bacteria find congenial. The engineered EcN naturally homes to and proliferates within these hypoxic tumour zones. Once there, it produces <strong>Romidepsin (FK228)</strong> — an FDA-approved anticancer drug — directly at the tumour site.</p>
<p>In mouse models, the targeted delivery approach produced significant tumour shrinkage with far lower systemic drug exposure than conventional administration.</p>
<h2>Why This Is Different</h2>
<p>Using bacteria to carry therapeutic payloads into tumours is not a new idea — researchers have been pursuing it for years. What makes this study notable is the combination of factors: a probiotic bacteria with an established safety profile in humans, a drug already approved by the FDA, and a delivery mechanism that exploits the tumour's own defences against it.</p>
<p>The tumour essentially becomes the factory floor. The bacterium goes to the tumour because the tumour is where it thrives. The drug is made locally. The side effects of systemic exposure are minimised.</p>
<h2>The Road to Human Trials</h2>
<p>Mouse models are not humans, and there remains substantial work before this approach enters clinical trials. But the use of EcN — rather than a more exotic or dangerous organism — means the safety groundwork for human use is already partly in place. The researchers describe the results as providing a strong foundation for clinical translation.</p>
<p>In the broader context of cancer research, this is one of several 2025-2026 studies exploring bacteria as cancer therapy vectors. The direction of travel is towards increasingly precise, locally-acting cancer treatments — and bacteria, surprisingly, may be one of the most promising delivery vehicles ever found.</p>
<p><em>Sources: ScienceDaily (March 21, 2026) · PLOS Biology · Drug Target Review</em></p>
